Patrycja Fiertek

Patrycja Fiertek

Auto-generated profile, based on publicly available information

Patrycja Fiertek

Railway Hospital in Pruszków, 05-800 Pruszków, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MBMichał Bereza
Michał Bereza
KKKacper Kmieć
Kacper Kmieć
ESEdyta Szymańska
Edyta Szymańska
MDMateusz Dembiński
Mateusz Dembiński
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
MRMarlena Rycyk
Marlena Rycyk
Background: Precision medicine, driven by advances in genomics, is reshaping the approach to diagnosis, risk assessment, and treatment planning in cardiac surgery. By analyzing genetic variation and molecular pathways, clinicians can move beyond standardized protocols toward individualized surgical care. Methods: This review synthesizes recent literature on the integration of genomic technologies - such as whole genome sequencing, gene expression profiling, and pharmacogenomics - into the preoperative, intraoperative, and postoperative phases of cardiac surgery. Sources include peer-reviewed articles, clinical trial data, and translational research reports published over the past 20 years. Results: Genomic profiling enables improved risk stratification, early detection of hereditary cardiovascular diseases, and identification of genetic biomarkers predictive of surgical outcomes. Pharmacogenomic insights allow optimization of perioperative drug therapy, reducing complications and enhancing recovery. Emerging applications include bioinformatics-driven surgical planning and integration of multi-omic data for real-time decision support. However, challenges remain regarding data interpretation, ethical considerations, and integration into clinical workflows. Conclusion: Precision medicine and genomics hold significant promise for improving patient-specific outcomes in cardiac surgery. Their successful implementation will require robust clinical evidence, interdisciplinary collaboration, and infrastructure to manage and interpret complex genomic data. Ongoing research is likely to expand their role from risk prediction to fully individualized surgical strategies.

29 July 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
PFPatrycja Fiertek
Patrycja Fiertek
KJKlaudia Jedlina
Klaudia Jedlina
KKKatarzyna Krupa
Katarzyna Krupa
MKMałgorzata Krzyżanowska
Małgorzata Krzyżanowska
APAnna Maria Pietrzak
Anna Maria Pietrzak
PPPatryk Pustuła
Patryk Pustuła
Schizophrenia is a severe psychiatric disorder affecting approximately 1% of the general population. Its pathogenesis is multifactorial, with both genetic predispositions and environmental factors contributing to disease onset. Numerous theoretical models have been proposed to elucidate the underlying mechanisms of schizophrenia, most of which are based on the pharmacological action of antipsychotic drugs and their observed clinical efficacy in symptom reduction. The predominant hypotheses implicate dysregulation of dopaminergic, serotonergic, and glutamatergic neurotransmission. The majority of currently available antipsychotic agents exert their therapeutic effects primarily by modulating the dopaminergic system. This narrow pharmacological focus substantially limits treatment options, particularly in cases of drug resistance or intolerance. Moreover, selective receptor targeting increases the likelihood of adverse effects, which frequently lead to nonadherence. Poor adherence, in turn, is associated with significant clinical deterioration and poses a major obstacle to functional recovery. The development of novel antipsychotic agents with alternative mechanisms of action—combining therapeutic efficacy with an improved side-effect profile—represents a promising direction in the pharmacotherapy of schizophrenia. In recent years, new compounds such as Caplyta, Lybalvi, and Cobenfy have received regulatory approval, offering expanded treatment possibilities and the potential to address current limitations in clinical practice.

25 August 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MBMichał Bereza
Michał Bereza
MDMateusz Dembiński
Mateusz Dembiński
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
ESEdyta Szymańska
Edyta Szymańska
JKJoanna Kaszczewska
Joanna Kaszczewska
KKKacper Kmieć
Kacper Kmieć
Pediatric patients undergoing cardiac surgery, particularly with cardiopulmonary bypass (CPB), are at high risk for significant bleeding and allogeneic blood transfusions due to their unique hemostatic profile. Tranexamic acid (TXA) is the primary antifibrinolytic agent used to mitigate this risk, but its efficacy, safety, and optimal administration in this population remain topics of debate. This article provides a comprehensive review and to synthesize the available evidence and identify critical knowledge gaps. Our analysis confirms that TXA significantly reduces postoperative blood loss and the need for allogeneic red blood cell and fresh frozen plasma transfusions. This effect was particularly notable in high-risk subgroups such as infants and cyanotic patients. Substantial heterogeneity was found across studies, primarily related to varying TXA dosing regimens and differing transfusion protocols, which limited the ability to define a single optimal dose. TXA is an effective agent for reducing bleeding and transfusion needs in pediatric cardiac surgery, but its use is associated with a potential, dose-dependent risk of seizures. The wide variability in dosing regimens and the lack of robust data on long-term neurological outcomes highlight a critical need for future large-scale, prospective trials. These studies should aim to standardize dosing protocols and definitively assess the true benefit-to-risk ratio of TXA in specific pediatric subgroups.

3 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MDMateusz Dembiński
Mateusz Dembiński
MBMichał Bereza
Michał Bereza
JPJulia Prabucka-Marciniak
Julia Prabucka-Marciniak
ESEdyta Szymańska
Edyta Szymańska
JPJakub Pysiewicz
Jakub Pysiewicz
HRHubert Rycyk
Hubert Rycyk
Vascular diseases are a major source of global morbidity and mortality, often requiring surgical intervention, but the long-term outcomes are frequently compromised by complications like graft failure and restenosis. Since traditional imaging methods often detect these issues only at an advanced stage, there is a critical need for more precise and earlier risk prediction tools. This comprehensive narrative review synthesizes existing literature on the predictive value of circulating and tissue-based biomarkers for these adverse outcomes. The study systematically examined major electronic databases including PubMed, Scopus, and Web of Science, utilizing keywords related to vascular surgery, outcomes (e.g., graft failure, restenosis), and biomarkers. The identified biomarkers were categorized into four principal groups: inflammatory, lipid-related, genetic, and novel/emerging markers. The review found that elevated levels of inflammatory markers—such as high-sensitivity C-reactive protein (hs-CRP) and various interleukins (IL-6, IL-1β, TNF-α, IL-18, IL-33)—are strongly associated with an increased risk of graft failure and restenosis. Conversely, anti-inflammatory interleukins like IL-10 and IL-19 were found to correlate with a reduced risk. Furthermore, an unfavorable lipid profile (high LDL, low HDL, or an elevated LDL/HDL ratio) was consistently linked to a higher incidence of these complications. The review also highlights the promising potential of genetic markers, such as specific single nucleotide polymorphisms (SNPs), and novel biomarkers like non-coding RNAs in developing personalized treatment strategies. The findings suggest that incorporating biomarker panels into routine clinical practice could significantly enhance preoperative risk stratification, enabling tailored perioperative therapy and more effective postoperative surveillance. By allowing for the early detection of biological evidence of graft compromise, this precision-medicine model has the potential to substantially improve long-term patient outcomes in vascular surgery.

16 July 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KKKatarzyna Kozon
Katarzyna Kozon
KKKatarzyna Krupa
Katarzyna Krupa
PFPatrycja Fiertek
Patrycja Fiertek
Adrianna BrzozowskaAdrianna Brzozowska
Adrianna Brzozowska
KNKarolina Niewczas
Karolina Niewczas
MSMarcin Sawczuk
Marcin Sawczuk
Dravet syndrome is a severe, early childhood epileptic encephalopathy, most often associated with a mutation in the SCN1a gene characterized by drug resistance and high neurological burden. For many years treatment was limited to non-specific antiepileptic drugs, but recently new, targeted therapies have appeared, which have significantly improved the prognosis of patients. Stiripentol, modulating GABAergic transmission, has been approved as an adjuctive treatment in the treatment of Dravet syndrome, showing a significant reduction in the frequency of seizures in combination with clobazam and valproic acid. In turn, fenfluramine, acting on serotonin receptors, among others, has proven also effective. Both drugs have been approved by the FDA and EMA, constitiuting a breakthrough in the treatment of Dravet syndrome Their introduction has significantly improved the quality of life of patients and opened up new perspectives in the treatment of developmental epilepsies.

18 July 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KKKatarzyna Krupa
Katarzyna Krupa
KKKatarzyna Kozon
Katarzyna Kozon
MKMałgorzata Krzyżanowska
Małgorzata Krzyżanowska
PFPatrycja Fiertek
Patrycja Fiertek
HKHanna Krupa
Hanna Krupa
ZBZuzanna Burkacka
Zuzanna Burkacka
Background. Insomnia is a common and burdensome condition in older adults, marked by difficulty falling or staying asleep, early awakenings, and non-restorative sleep. Its prevalence increases with age and is linked to cognitive decline, depression, falls, and reduced quality of life. Physiological aging and polypharmacy complicate treatment in this group. Aim. This paper reviews current pharmacological options for managing insomnia in the geriatric population, focusing on efficacy, safety, and adherence to clinical guidelines. Materials and Methods. A literature review was conducted using PubMed, Scopus, and Google Scholar. Sources included randomized controlled trials, systematic reviews, meta-analyses, observational studies, and guidelines published up to 2024. Keywords included “insomnia,” “elderly,” “pharmacological treatment,” “hypnotics,” and related terms. Only studies involving patients aged 65+ were analyzed. Data on efficacy, safety, dosing, duration, and guideline recommendations were extracted. Analysis of Literature. Current guidelines prioritize non-pharmacological treatments. Pharmacotherapy may be considered when behavioral methods are ineffective or unavailable. Prolonged-release melatonin and low-dose doxepin offer the best safety-efficacy balance. Orexin receptor antagonists show promise but are not yet available in Poland. Sedating antidepressants like trazodone, mirtazapine, and mianserin may be cautiously used in patients with comorbid depression or anxiety. Z-drugs and benzodiazepines, despite their efficacy, pose significant risks such as falls, dependence, and cognitive decline. Antihistamines and antipsychotics are generally not recommended due to unfavorable safety profiles. Conclusion. Pharmacological treatment of insomnia in older adults should be cautious and individualized. Non-drug therapies remain the first-line option. When medications are necessary, the safest agents should be used at the lowest effective doses for the shortest duration. Ongoing research is essential to expand safe therapeutic options.